Which areas are still left in biologics responsive Korean patients with moderate to severe plaque psoriasis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Psoriasis localized to certain body areas, such as the scalp, nails, palms, soles,intertriginous regions, and genital regions, is reportedly difficult to treat. Objective: To investigate the biologics-resistant areas in South Korean patients with psoriasistreated with biologics. Methods: The study included 50 patients with chronic moderate to severe plaque psoriasisfrom the Pusan National University Hospital and Chosun University Hospital between October2019 and September 2020. The patients had at least one psoriatic lesion, were treatedwith biologics for more than six months, and exhibited a partial or good response (reachinga Psoriasis Area and Severity Index [PASI] score of 1~5 after biologics treatment). Results: A total of 50 patients with psoriasis (32 male, mean±standard deviation 47.8±11years), with a median PASI score of 1.8, were included. The most common biologics-resistantareas were the anterior lower leg (56.0%), followed by the knee (48.0%) and posteriorlower leg (42.0%). The proportion of biologics-resistant areas were obtained for body regionstraditionally considered as difficult-to-treat entities, including the fingernails (10.0%), toenails(14.0%), scalp (38.0%), palm (12.0%), sole (14.0%), and genital areas (10.0%). Conclusion: This study determined the biologics-resistant areas in South Korean patients,successfully treated with biologics, in a real-world clinical setting.
Abstract
Background: Psoriasis localized to certain body areas, such as the scalp, nails, palms, soles,intertriginous regions, and genital regions, is reportedly difficult to treat. Objective: To investigate the biologics-resistant areas in South Korean patients with psoriasistreated with biologics. Methods: The study included 50 patients with chronic moderate to severe plaque psoriasisfrom the Pusan National University Hospital and Chosun University Hospital between October2019 and September 2020. The patients had at least one psoriatic lesion, were treatedwith biologics for more than six months, and exhibited a partial or good response (reachinga Psoriasis Area and Severity Index [PASI] score of 1~5 after biologics treatment). Results: A total of 50 patients with psoriasis (32 male, mean±standard deviation 47.8±11years), with a median PASI score of 1.8, were included. The most common biologics-resistantareas were the anterior lower leg (56.0%), followed by the knee (48.0%) and posteriorlower leg (42.0%). The proportion of biologics-resistant areas were obtained for body regionstraditionally considered as difficult-to-treat entities, including the fingernails (10.0%), toenails(14.0%), scalp (38.0%), palm (12.0%), sole (14.0%), and genital areas (10.0%). Conclusion: This study determined the biologics-resistant areas in South Korean patients,successfully treated with biologics, in a real-world clinical setting.
참고문헌 (13)
- Parisi R, "Global epidemiology of psoriasis : a systematic review of incidence and prevalence", J Invest Dermatol, 133, pp.377~385 (2013)
- 이진용, "Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database", Annals of Dermatology, 29(6), pp.761~767 (2017), 대한피부과학회
- van de Kerkhof PC, "Psoriasis of the scalp. Diagnosis and management", Am J Clin Dermatol, 2, pp.159~165 (2001)
- Wozel G, "Psoriasis treatment in difficult locations : scalp, nails, and intertriginous areas", Clin Dermatol, 26, pp.448~459 (2008)
- Larko O, "Problem sites : scalp, palm and sole, and nail", Dermatol Clin, 13, pp.771~777 (1995)
- McKay C, "Biologic therapy in psoriasis : navigating the options", Cutis, 102, pp.13~17 (2018)
- Revicki DA, "Relationship between clinical response to therapy and healthrelated quality of life outcomes in patients with moderate to severe plaque psoriasis", Dermatology, 216, pp.260~270 (2008)
- Hjuler KF, "Localization of treatment-resistant areas in patients with psoriasis on biologics", Br J Dermatol, 181, pp.332~337 (2019)
- Reich K, "Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis : an analysis from VOYAGE 1 and VOYAGE 2", J Dermatol, 46, pp.1141~1152 (2019)
- Youn SW, "Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis : posthoc analysis from the phase III, double-blind, placebo-and activecomparator-controlled VOYAGE 1", 2 trials, 2022, pp.33, 535~541
- Merola JF, "Underdiagnosed and undertreated psoriasis : nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails", Dermatol Ther, 31, pp.e12589~ (2018)
- Sarma N, "Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas : palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis", Indian J Dermatol, 62, pp.113~122 (2017)
- Singh S, "Induction of psoriasis and Koebner's phenomenon", J Dermatol, 37, pp.568~569 (2010)